We have moved to new location, Please click on contact us  
Home  >  News
Eppen_MCX50_Dec2022
Pioma_Lactitol_3_Jan23.gif
you can get e-magazine links on WhatsApp. Click here
Biotechnology + Font Resize -

UK MHRA grants authorization to Pfizer/BioNTech Covid-19 vaccine for use in infants and children aged 6 months to 4 years

United Kingdom
Wednesday, December 7, 2022, 09:00 Hrs  [IST]

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted for a new presentation of the Pfizer/BioNTech Covid-19 vaccine (Comirnaty) for use in infants and children aged 6 months to 4 years.

The agency has authorised the vaccine in this new age group after it has been found to meet the UK regulator’s standards of safety, quality and effectiveness, with no new safety concerns identified. This decision has been endorsed by the Commission on Human Medicines, after a careful review of the evidence.

This presentation is specially designed for this new age group and given at a lower dose compared to that used in individuals aged 5 to 11 years (3 micrograms compared with 10 micrograms). It is given as three injections in the upper arm, with the first two doses given 3 weeks apart, followed by a third dose given at least 8 weeks after the second dose.

In reaching their decision, the MHRA’s experts carefully reviewed data from an ongoing clinical trial involving 4,526 participants. The common, expected side effects (reactogenicity) were in-keeping with what can be anticipated from a vaccine in this age group.

It will be for the Joint Committee on Vaccination and Immunisation (JCVI) to determine if the vaccine will be recommended for use in this age group as part of the UK’s COVID-19 vaccination programme.

The Commission on Human Medicines (CHM) advises ministers on the safety, efficacy and quality of medicinal products. The CHM is an advisory non-departmental public body, sponsored by the?Department of Health and Social Care.

This new line extension granted by the MHRA is valid in Great Britain only and was authorised via the European Commission (EC) Decision Reliance Route. This is when the marketing authorisation application made by the company references the decision made by the EMA’s Committee for Medicinal Products for Human Use (CHMP). In such cases, the MHRA considers the application together with due consideration of the EC decision, before making an independent decision on the quality, safety and effectiveness of the vaccine.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
India Lab Expo
Pharma_Live_Expo_2023
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |